I

mmunotherapy is a delicate balance: You have to rally a patient’s immune cells into action to kill diseased cells, but keep them away from healthy tissues. Vedantra Pharmaceuticals, a startup based in Cambridge, Mass., is working on a way to refine that process.

The company has developed next-gen nanoparticle vaccines — engineering vesicles that help ferry the therapy straight to the lymph nodes. That helps the body generate a stronger immune response. The work, based on research at MIT, is still preclinical, but Vedantra hopes it can be used to bolster cancer treatments. It’s focusing first on malignancies provoked by the HPV virus — such as cervical and head and neck cancer.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.